Upcoming trials of TCR in breast cancer include a phase Ib trial (NCT05989828) for patients with metastatic TNBC which expresses HLA-A*O2 restricted NY-ESO-1, a phase I trial (NCT05877599) of HLA-A*02 restricted NT-175 in solid tumors including breast cancer, and two phase I studies (NCT05483491, NCT05035407) of HLA-A*01-restricted KK-LC-1 in solid tumors including breast cancer (Table 8). Here, CT83 is linked to breast carcinoma.